Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis

Randomized controlled trial will evaluate both symptom progression and underlying biology SAN MATEO, Calif. — Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will... The post Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis appeared first on Montreal Gazette .

Original source: Montreal Gazette